Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 11 studies | 27% ± 13% | |
oligodendrocyte precursor cell | 10 studies | 35% ± 13% | |
mast cell | 9 studies | 28% ± 17% | |
oligodendrocyte | 9 studies | 27% ± 8% | |
GABAergic neuron | 8 studies | 38% ± 16% | |
epithelial cell | 8 studies | 31% ± 17% | |
astrocyte | 7 studies | 32% ± 13% | |
interneuron | 6 studies | 40% ± 18% | |
macrophage | 5 studies | 21% ± 6% | |
neuron | 5 studies | 45% ± 21% | |
retina horizontal cell | 5 studies | 36% ± 17% | |
type II pneumocyte | 5 studies | 23% ± 9% | |
hematopoietic precursor cell | 4 studies | 28% ± 13% | |
hepatocyte | 4 studies | 35% ± 10% | |
glutamatergic neuron | 4 studies | 56% ± 9% | |
endothelial cell of lymphatic vessel | 4 studies | 29% ± 3% | |
GABAergic interneuron | 3 studies | 24% ± 8% | |
microglial cell | 3 studies | 27% ± 4% | |
ciliated cell | 3 studies | 20% ± 2% | |
basal cell | 3 studies | 19% ± 3% | |
abnormal cell | 3 studies | 39% ± 24% | |
hematopoietic stem cell | 3 studies | 24% ± 6% | |
megakaryocyte-erythroid progenitor cell | 3 studies | 38% ± 16% | |
transit amplifying cell | 3 studies | 25% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 1867.58 | 245 / 245 | 100% | 21.18 | 502 / 502 |
stomach | 100% | 1699.63 | 359 / 359 | 100% | 23.12 | 286 / 286 |
brain | 100% | 1187.12 | 2636 / 2642 | 100% | 32.03 | 704 / 705 |
breast | 100% | 1623.29 | 459 / 459 | 100% | 21.94 | 1113 / 1118 |
esophagus | 100% | 1393.55 | 1445 / 1445 | 99% | 18.87 | 182 / 183 |
intestine | 100% | 1349.81 | 966 / 966 | 99% | 18.07 | 524 / 527 |
lung | 100% | 1601.05 | 577 / 578 | 99% | 19.60 | 1147 / 1155 |
ovary | 100% | 3149.32 | 180 / 180 | 99% | 14.07 | 426 / 430 |
liver | 100% | 1816.78 | 226 / 226 | 99% | 18.92 | 402 / 406 |
bladder | 100% | 1664.90 | 21 / 21 | 99% | 25.91 | 499 / 504 |
thymus | 100% | 1292.22 | 653 / 653 | 99% | 13.24 | 598 / 605 |
pancreas | 100% | 1280.08 | 328 / 328 | 98% | 10.53 | 175 / 178 |
adrenal gland | 100% | 5839.71 | 258 / 258 | 96% | 19.09 | 221 / 230 |
uterus | 100% | 1336.03 | 170 / 170 | 96% | 14.98 | 441 / 459 |
skin | 100% | 1511.71 | 1809 / 1809 | 94% | 12.54 | 442 / 472 |
kidney | 100% | 1018.91 | 89 / 89 | 93% | 9.90 | 835 / 901 |
adipose | 100% | 1512.24 | 1204 / 1204 | 0% | 0 | 0 / 0 |
muscle | 100% | 1707.17 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 1242.15 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 22.95 | 1 / 1 |
blood vessel | 100% | 1276.45 | 1334 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 8.72 | 28 / 29 |
heart | 97% | 1117.33 | 831 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 93% | 12.16 | 42 / 45 |
peripheral blood | 81% | 802.90 | 754 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 51% | 3.13 | 41 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0050673 | Biological process | epithelial cell proliferation |
GO_0055074 | Biological process | calcium ion homeostasis |
GO_0006366 | Biological process | transcription by RNA polymerase II |
GO_0016567 | Biological process | protein ubiquitination |
GO_0043434 | Biological process | response to peptide hormone |
GO_0010628 | Biological process | positive regulation of gene expression |
GO_0071391 | Biological process | cellular response to estrogen stimulus |
GO_0050680 | Biological process | negative regulation of epithelial cell proliferation |
GO_0070562 | Biological process | regulation of vitamin D receptor signaling pathway |
GO_0042981 | Biological process | regulation of apoptotic process |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_1901796 | Biological process | regulation of signal transduction by p53 class mediator |
GO_0030163 | Biological process | protein catabolic process |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0031647 | Biological process | regulation of protein stability |
GO_0005726 | Cellular component | perichromatin fibrils |
GO_0005739 | Cellular component | mitochondrion |
GO_0000791 | Cellular component | euchromatin |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0001673 | Cellular component | male germ cell nucleus |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0035064 | Molecular function | methylated histone binding |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0016922 | Molecular function | nuclear receptor binding |
GO_0003682 | Molecular function | chromatin binding |
GO_0070577 | Molecular function | lysine-acetylated histone binding |
GO_0034056 | Molecular function | estrogen response element binding |
GO_0005102 | Molecular function | signaling receptor binding |
GO_0004672 | Molecular function | protein kinase activity |
GO_0008270 | Molecular function | zinc ion binding |
GO_0002039 | Molecular function | p53 binding |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | TRIM24 |
Protein name | Transcription intermediary factor 1-alpha (TIF1-alpha) (EC 2.3.2.27) (E3 ubiquitin-protein ligase TRIM24) (RING finger protein 82) (RING-type E3 ubiquitin transferase TIF1-alpha) (Tripartite motif-containing protein 24) |
Synonyms | RNF82 TIF1A TIF1 |
Description | FUNCTION: Transcriptional coactivator that interacts with numerous nuclear receptors and coactivators and modulates the transcription of target genes. Interacts with chromatin depending on histone H3 modifications, having the highest affinity for histone H3 that is both unmodified at 'Lys-4' (H3K4me0) and acetylated at 'Lys-23' (H3K23ac). Has E3 protein-ubiquitin ligase activity. During the DNA damage response, participates in an autoregulatory feedback loop with TP53. Early in response to DNA damage, ATM kinase phosphorylates TRIM24 leading to its ubiquitination and degradation. After sufficient DNA repair has occurred, TP53 activates TRIM24 transcription, ultimately leading to TRIM24-mediated TP53 ubiquitination and degradation . Plays a role in the regulation of cell proliferation and apoptosis, at least in part via its effects on p53/TP53 levels. Up-regulates ligand-dependent transcription activation by AR, GCR/NR3C1, thyroid hormone receptor (TR) and ESR1. Modulates transcription activation by retinoic acid (RA) receptors, including RARA. Plays a role in regulating retinoic acid-dependent proliferation of hepatocytes (By similarity). Participates also in innate immunity by mediating the specific 'Lys-63'-linked ubiquitination of TRAF3 leading to activation of downstream signal transduction of the type I IFN pathway . Additionally, negatively regulates NLRP3/CASP1/IL-1beta-mediated pyroptosis and cell migration probably by ubiquitinating NLRP3 . . |
Accessions | ENST00000415680.6 [O15164-2] O15164 ENST00000343526.9 [O15164-1] |